Treatment News : Tivicay Suppresses HIV Well, Even With Nuke Resistance

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » August 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

August 7, 2014

Tivicay Suppresses HIV Well, Even With Nuke Resistance

AIDS 2014ViiV Healthcare’s recently approved integrase inhibitor Tivicay (dolutegravir) suppresses HIV at high rates even among treatment-experienced people with resistance to nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs, or nukes), aidsmap reports. Researchers conducted a post-hoc combined analysis of the virologic outcomes of various Phase III trials of regimens based on Tivicay. They presented their findings at the 20th International AIDS Conference (AIDS 2014) in Melbourne, Australia.

The SPRING-2, SINGLE and FLAMINGO trials included treatment-naive participants, and the SAILING study looked at Tivicay’s success in suppressing HIV in treatment-experienced participants who were integrase inhibitor-naive and who had resistance to two or more other antiretroviral classes.

None of the treatment-naive participants taking Tivicay with two nukes developed any drug resistance through 48 weeks or 96 weeks.

The SAILING study compared Tivicay-based regimens with those based on the integrase inhibitor Isentress (raltegravir). It found that 71 percent of those in the Tivicay group had a fully suppressed viral load at 48 weeks, compared with 64 percent of those taking Isentress. Among those with NRTI resistance who took two nukes as a background regimen, none experienced virologic failure when taking Tivicay, while 22 percent of those taking Isentress experienced virologic failure.

Among those in SAILING who did experience virologic failure, significantly fewer in the Tivicay group developed drug resistance when compared with the Isentress group: A respective 1 percent and 5 percent developed integrase inhibitor resistance, and a respective 1 and 3 percent developed resistance to the other drugs in the regimen.

To read the aidsmap story, click here.

To read the conference abstract, click here.

Search: Tivicay, dolutegravir, aidsmap, SAILING, SINGLE, SPRING-2, Isentress, raltegravir, 20th International AIDS Conference, AIDS 2014.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.